Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...

Full description

Bibliographic Details

Published in:	Frontiers in pharmacology Vol. 15; p. 1392209
Main Authors:	Jiang, Shuwen, Li, Xiangkun, Xue, Weifang, Xia, Sumei, Wang, Jian, Sai, Yang, Dai, Guangxiu, Su, Weiguo
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 2024
Subjects:	drug–drug interaction hematological malignancies in vitro in vivo extrapolation pharmacokinetics PI3Kδ tissue distribution hematological malignancies pharmacokinetics PI3Kδ drug–drug interaction in vitro in vivo extrapolation tissue distribution
ISSN:	1663-9812, 1663-9812
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!